Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study | Zendy

Andre Nyandwe Hamama Bulabula | Zendy; Jenelson | Zendy; Eric Mulume Musafiri | Zendy; Rhoderick Machekano | Zendy; Nadia A. SamAgudu | Zendy; Andreas H. Diacon | Zendy; Maunank Shah | Zendy; Jacob Creswell | Zendy; Grant Theron | Zendy; Robin M. Warren | Zendy; Karen R. Jacobson | Zendy; Jean-Paul Chirambiza | Zendy; Dieudonné Kalumuna | Zendy; Bertin C. Bisimwa | Zendy; Patrick DMC Katoto | Zendy; Michel Kaswa | Zendy; Freddy Birembano | Zendy; Liliane Kitete | Zendy; Martin P. Grobusch | Zendy; Zacharie Kashongwe | Zendy; Jean B. Nachega | Zendy

Open Access

Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study

Author(s) -

Andre Nyandwe Hamama Bulabula,

Jenelson,

Eric Mulume Musafiri,

Rhoderick Machekano,

Nadia A. SamAgudu,

Andreas H. Diacon,

Maunank Shah,

Jacob Creswell,

Grant Theron,

Robin M. Warren,

Karen R. Jacobson,

Jean-Paul Chirambiza,

Dieudonné Kalumuna,

Bertin C. Bisimwa,

Patrick DMC Katoto,

Michel Kaswa,

Freddy Birembano,

Liliane Kitete,

Martin P. Grobusch,

Zacharie Kashongwe,

Jean B. Nachega

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy1105

Subject(s) - medicine , sputum , interquartile range , tuberculosis , odds ratio , confidence interval , rifampicin , logistic regression , cohort , pathology

Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research